Clinical trials across England and Scotland are underway to investigate if an existing diabetes medicine can potentially work as a disease-modifying option for early-stage Alzheimer’s disease. Novo Nordisk is now working alongside Join Dementia Research to investigate if the medicine, known as semaglutide, could also benefit people living with early Alzheimer’s disease. What the study […]